Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release

Neuroscience

Volumn 84, Issue 2, 1998, Pages 413-429

  Gobert, A ^a   Rivet, J M ^a   Audinot, V ^a   Newman Tancredi, A ^a   Cistarelli, L ^a   Millan, M J ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Autoreceptor; Depression; Frontal cortex; Heteroceptor; Microdialysis; Monoamine

Indexed keywords

2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 [3 (2 DIMETHYLAMINOETHYL) 1H INDOL 5 YL] N (4 METHOXYBENZYL)ACRYLAMIDE; ALPHA ADRENERGIC RECEPTOR; AUTORECEPTOR; DEXMEDETOMIDINE; DOPAMINE; DOPAMINE RECEPTOR; GUANABENZ; ISOMOLPAN; MONOAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NORADRENALIN; PRAZOSIN; RACLOPRIDE; RECEPTOR; SEROTONIN; SEROTONIN 1B ANTAGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; COULOMETRY; DIALYSATE; DOPAMINE RELEASE; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BENZOPYRANS; DOPAMINE; DOPAMINE AGONISTS; FRONTAL LOBE; GUANABENZ; GUINEA PIGS; HOMEOSTASIS; IDAZOXAN; IMIDAZOLES; INDOLES; MALE; MEDETOMIDINE; MODELS, NEUROLOGICAL; MOTOR ACTIVITY; NOREPINEPHRINE; OXADIAZOLES; PIPERAZINES; PRAZOSIN; RACLOPRIDE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SALICYLAMIDES; SEROTONIN;

EID: 0031890807     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00565-4     Document Type: Article

References (136)

1. Abercrombie E. D., Keefe K. A., DiFrischia S. S., Zigmond M. J. Differential effects of stress on in vivo dopamine release in striatum, nucleus accumbens and medial frontal cortex. J. Neurochem. 52:1989;1655-1658.
2. 3 dopamine receptor gene is associated with hyperactivity in mice. Proc. natn. Acad. Sci. U.S.A. 93:1996;1945-1949.
3. Agneter E., Hoffmann I. S., Singer E. A., Cubeddu L. X. Behavior of the mesocortical dopamine terminals during single and repetitive stimulation: comparison with nigrostriatal neurons. J. Pharmac. exp. Ther. 269:1994;470-476.
4. 3H]-noradrenaline release in rabbit hippocampus and human neocortex. Br. J. Pharmac. 116:1995;1769-1774.
5. Andersson J. L., Marcus M., Nomikos G. G., Svensson T. H. Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn-Schmiedeberg's Arch. Pharmac. 349:1994;236-243.
6. Arborelius L., Nomikos G. G., Hacksell U., Svensson T. H. (R)-8-OH-DPAT preferentially increases dopamine release in the rat medial prefrontal cortex. Acta physiol. scand. 148:1993;465-466.
7. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedeberg's Arch. Pharmac. 347:1993;353-362.
8. 3 subtypes. Brain Res. 649:1994;95-110.
9. Aston-Jones G., Chiang C., Alexinsky T. Discharge of noradrenergic locus coerulus neurons in behaving rats and monkeys suggests a role in viligance. Prog. Brain Res. 88:1991;501-520.
10. Bannon M. J., Roth R. H. Pharmacology of mesocortical dopamine neurons. Pharmac. Rev. 35:1983;53-68.
11. Baraban J. M., Aghajanian G. K. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology. 19:1980;355-363.
12. 1A receptors postsynaptic to serotoninergic neurones mediate spontaneous tail-flicks in the rat. J. Pharmac. exp. Ther. 264:1993;95-104.
13. 1B receptors. J. Pharmac. exp. Ther. 250:1989;37-43.
14. 1 receptor agonist RU-24969 decreases 5-hydroxytryptamine (5-HT) release and metabolism in the rat frontal cortex in vitro and in vivo. Br. J. Pharmac. 86:1985;209-216.
15. 1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 33:1994;367-386.
16. 2A receptor mRNA in human brain. Brain Res. 676:1995;157-168.
17. 2-adrenergic receptors. Fedn Proc. Fedn Am. Socs exp. Biol. 6:1992;832-839.
18. Cameron D. L., Wessendorf M. W., Williams J. T. A subset of ventral tegmental area neurons is inhibited by dopamine, 5-hydroxytryptamine and opioids. Neuroscience. 77:1997;155-166.
19. Carlson J. N., Fitzgerald L. W., Keller R. W., Glick S. D. Lateralized changes in prefrontal cortical dopamine activity induced by controllable and uncontrollable stress in the rat. Brain Res. 630:1993;178-187.
20. Cenci M. A., Kalén P., Mandel R. J., Björklund A. Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res. 581:1992;217-228.
21. 3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse. 10:1992;264-266.
22. Chen N. H., Reith M. E. A. Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systematically with (±)-8-hydroxy-2-(di-n-propylamino)tetralin. J. Neurochem. 64:1995;1585-1597.
23. Cheng C. H. K., Costall B., Ge J., Naylor R. J. The profiles of interaction of yohimbine with anxiolytic and putative agents to modify 5-HT release in the frontal cortex of freely-moving rats. Br. J. Pharmac. 110:1993;1079-1084.
24. Chiu T.-H., Chen M.-J., Yang Y.-R., Yang J.-J., Tang F.-I. Action of dexmedetomidine on rat locus coeruleus neurones: intracellular recording in vitro. Eur. J. Pharmac. 285:1995;261-268.
25. Clement H. W., Gemsa D., Wesemann W. Serotonin-norepinephrine interactions: a voltammetric study on the effect of serotonin receptor stimulation followed in the N. raphe dorsalis and the locus coeruleus of the rat. J. neural Transm. 88:1992;11-23.
26. 1A receptor. In Psychopharmacology: The Fourth Generation in Progress (eds Bloom F. E. and Kupfer D. J.), pp. 1301-1310. Raven, New York.
27. Cuadra G., Giacobini E. Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo. J. Pharmac. exp. Ther. 275:1995;228-236.
28. 2-adrenoceptor agonists, medetomidine, clonidine and UK 14,304, on extraneuronal levels of noradrenaline in the rat frontal cortex: evaluation using in vivo microdialysis and synaptosomal uptake studies. Br. J. Pharmac. 114:1995;1717-1723.
29. 3 receptor ligand. Eur. J. Pharmac. 249:1993;R9-R10.
30. 1B/D receptor antagonists. Neurosci. Lett. 188:1995;41-44.
31. Dennis T., L'Heureux R., Carter C., Scatton B. Presynaptic alpha-2 adrenoceptors play a mojor role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J. Pharmac. exp. Ther. 241:1987;642-649.
32. Descarries L., Lemay B., Doucet G., Berger B. Regional and laminar density of the dopamine innervation in adult rat cerebral cortex. Neuroscience. 21:1987;807-821.
33. 2-adrenoceptor antagonism and depression. Drug News Perspect. 4:1991;197-203.
34. 2 receptor activation decreases noradrenaline release in rat hipoocampus in vivo. Br. J. Pharmac. 107:1992;240-245.
35. 2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology. 33:1994;411-421.
36. Fedele E., Andrioli G. C., Ruelle A., Raiteri M. Release-regulating dopamine autoreceptors in human cerebral cortex. Br. J. Pharmac. 110:1993;20-22.
37. Ferré S., Cortés R., Artigas F. Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J. Neurosci. 14:1994;4839-4846.
38. 1A receptor antagonist. Behav. Brain Res. 73:1996;337-353.
39. Fornal C. A., Metzler C. W., Veasey A. C., McCreary A. C., Dourish C. T., Jacobs B. L. Single-unit recordings from freely-moving animals provide evidence that WAY-100,635, but not (S)-WAY-100135, blocks the action of endogenous serotonin at the 5-HT autoreceptor. Br. J. Pharmac. 112:1994;92.
40. 3H]5-hydroxytryptamine release from slices of the hippocampus of the rat. Eur. J. Pharmac. 81:1982;97-106.
41. 3H]5-hydroxytryptamine release from rat brain cortex synaptosomes. J. Pharm. Pharmac. 45:1993;811-814.
42. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J. Pharmac. exp. Ther. 275:1995;899-913.
43. 3 (auto) receptors inhibit dopamine release in the frontal cortex of freely moving rats in vivo. J. Neurochem. 66:1996;2209-2212.
44. 1B receptors with WAY 100,635 and GR 127,935. J. Neurochem. 68:1997;1159-1163.
45. 2 receptors. Eur. J. Pharmac. 154:1988;285-291.
46. 2 receptors: involvement of the prepositus hypoglossal nucleus. Neuropharmacology. 30:1991;1309-1318.
47. 1A receptors in rat brain membranes. Eur. J. Pharmac. 288:1995;173-186.
48. Grenhoff J., Nisell M., Ferré S., Aston-Jones G., Svensson T. H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J. neural Transm. 93:1993;11-25.
49. Gresch P. J., Sved A. F., Zigmond M. J., Finlay J. M. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J. Neurochem. 65:1995;111-116.
50. Guan X.-M., McBride W. J. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res. Bull. 23:1989;541-547.
51. 1A receptor antagonist, WAY 100,635, is dependent on the phase of the light-dark cycle. In Monitoring Molecules in Neuroscience, Proceedings of the 6th International Conference on In Vivo Methods (eds Louilot A., Durkin T., Spampinato U. and Cador M.), pp. 211-212.
52. Hand T. H., Hu X. T., Wang R. Y. Differential effects of acute clozapine and haloperidol on the activity of ventral (A10) and nigrostriatal (A9) dopamine neurons. Brain Res. 415:1987;257-269.
53. 1A receptors in prefrontal and temporal cortices of brain from patients with chronic schizophrenia. Life Sci. 48:1990;355-363.
54. 1-adrenoceptors in the inhibition of 5-HT release. I. BMY7378 and prazosin. Neuropharmacology. 34:1995;615-620.
55. 1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci. 48:1991;1779-1786.
56. 1B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)-penbutolol. J. Pharmac. exp. Ther. 265:1993;707-712.
57. 1B receptor agonist CP-93,129 supresses rat hippocampal 5-HT release in vivo: comparison with RU 14969. Eur. J. Pharmac. 209:1991;249-252.
58. 1D receptor antagonist, on brain 5-HT metabolism, extracellular 5-HT concentration and behaviour in the guinea pig. Neuropharmacology. 34:1995;383-392.
59. Invernizzi R., Carli M., Di Clemente A., Samanin R. Administration of 8-hydroxy-2-(di-n-propylamino)tetralin in raphe nuclei dorsalis and medianus reduces serotonin synthesis in the rat brain: differences in potency and regional sensitivity. J. Neurochem. 56:1991;243-247.
60. B synaptic potential in rat dopamine neurons. J. Neurosci. 12:1992;2000-2006.
61. Jordan S., Kramer G. L., Zukas P. K., Moeller M., Petty F. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse. 18:1994;294-297.
62. Kalén P., Strecker R. E., Rosengren E., Bjorklund A. Endogenous release of neuronal serotonin and 5-hydroxyindoleacetic acid in the caudate-putamen of the rat as revealed by intracerebral dialysis coupled to high-performance liquid chromatography with fluorimetric detection. J. Neurochem. 51:1988;1422-1435.
63. Kalivas P. W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev. 18:1993;75-113.
64. 1A receptor agonist. Molec. Neuropharmac. 2:1992;283-288.
65. Kelland M. D. and Chiodo L. A. (1996) Serotoninergic modulation of midbrain dopamine systems. In The Modulation of Dopaminergic Neurotransmission by Other Neurotransmitters (ed. Ashby C. R. Jr), pp. 87-122. CRC Press, Boca Raton, FL.
66. 2-adrenoceptors modulating hippocampal norepinephrine release in rat. Brain Res. 674:1995;238-244.
67. Kosofsky B. E., Molliver M. E. The serotoninergic innervation of cerebral cortex: different classes of axon terminals arise from dorsal and medial raphe nuclei. Synapse. 1:1987;153-168.
68. Kotrla K. J., Weinberger D. R. Brain imaging in schizophrenia. A. Rev. Med. 46:1995;113-122.
69. 1A autoreceptors of the dorsal and median raphe nuclei. J. Pharmac. exp. Ther. 269:1994;1268-1279.
70. Kreiss D. S., Wieland S., Lucki I. The presence of a serotonin uptake inhibitor alters pharmacological manipulations of serotonin release. Neuroscience. 52:1993;295-301.
71. 1A receptors. Eur. J. Pharmac. 260:1994;79-83.
72. 1A autoreceptors enhances dopamine (DA) and noradrenaline (NAD) release in rat frontal cortex: influence of S 15535, WAY 100,635 and 8-OH-DPAT. Eur. Neuropsychopharmac. 6:1996;S4.121-S4.122.
73. 1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. J. Pharmac. exp. Ther. 280:1997;1241-1249.
74. 2C receptors modulate the activity of mesocortical and mesolimbic dopaminergic pathways: a combined dialysis and electrophysiological analysis. Soc. Neurosci. Abstr. 23:1997;386.13.
75. Li M.-Y., Yan Q.-S., Coffey L. L., Reith M. E. A. Extracellular dopamine, norepinephrine, and serotonin in the nucleus accumbens of freely moving rats during intracerebral dialysis with cocaine and other monoamine uptake blockers. J. Neurochem. 66:1996;559-568.
76. 2A-adrenergic receptor reveals its role in multiple physiological settings. The Eighth International Catecholamine Symposium, p. 154.
77. 1A agonists in the learned helplessness paradigm in rats. Psychopharmacology. 104:1991;275-278.
78. 1A binding sites in frontal cortex of suicide victims. J. neural Transm. 85:1991;181-194.
79. 2-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmac. 345:1992;410-416.
80. 1 receptor agonist, RU 24969, inhibits the efflux of 5-hydroxytryptamine from rat frontal cortex slices by stimulation of the 5-HT autoreceptor. J. Pharm. Pharmac. 37:1985;434-437.
81. 2A-ARs in the control of nociception, motor behaviour and hippocampal synthesis of noradrenaline. J. Pharmac. exp. Ther. 270:1994;958-972.
82. 1A antagonists. J. Pharmac. exp. Ther. 268:1994;337-352.
83. 2 receptors elicits prolactin secretion and catalepsy. J. Pharmac. exp. Ther. 275:1995;885-898.
84. 2A-adrenergic receptors in relation to modulation of cortical monoamine release and potential antidepressant properties. J. Pharmac. exp. Ther. 282:1997;132-147.
85. Moghaddam B., Bunney B. S. Differential effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54:1990;1755-1760.
86. 1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br. J. Pharmac. 120:1997;737-739.
87. 2 and alpha-2 presynaptic receptors. Life Sci. 48:1990;283-289.
88. Ozaki N., Nakahara D., Miura H., Kasahara Y., Nagatsu T. Effect of apomorphine on in vivo release of dopamine and its metabolites in the prefrontal cortex and the striatum, studied by a microdialysis method. J. Neurochem. 53:1989;1861-1864.
89. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic, Sydney.
90. Pessia M., Jiang Z. G., North R. A., Johnson S. W. Actions of 5-hydroxytryptamine on ventral tegmantal area neurons of the rat in vitro. Brain Res. 654:1994;324-330.
91. 1D receptors regulate 5-HT release in the rat raphe nuclei. In vivo voltammetry and in vitro superfusion studies. Neuropsychopharmacology. 13:1995;249-260.
92. Prisco S., Pagannone S., Esposito E. Serotonin-dopamine interaction in the ventral tegmental area: an electrophysiological study in vivo. J. Pharmac. exp. Ther. 271:1994;83-90.
93. 1A agonist ±8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse. 18:1994;218-224.
94. 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat. Br. J. Pharmac. 116:1995;2081-2089.
95. 2-adrenergic subtypes. J. Pharmac. exp. Ther. 270:1994;946-957.
96. 3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay. Molec. Brain Res. 33:1995;97-103.
97. Rivet J.-M., Gobert A., Cistarelli L., Girardon S., Muller O., Lavielle G., Millan M. J. The novel, atypical antipsychotic, S 16924, enhances dopamine (DA) and noradrenaline (NAD) release, and decreases serotonin (5-HT) release, in frontal cortex of freely-moving rats. Soc. Neurosci. Abstr. 22:1996;467.1.
98. 2-dopamine receptors modulating noradrenaline release in the rat frontal cortex. Eur. J. Pharmac. 163:1989;393-395.
99. Roth R. H. and Elsworth J. D. (1995) Biochemical pharmacology of midbrain dopamine neurons. In Psychopharmacology: The Fourth Generation of Progress (eds Bloom F. E. and Kupfer D. J.), pp. 227-243. Raven, New York.
100. Saito H., Matsumoto M., Togashi H., Yoshioka M. Functional interaction between serotonin and other neuronal systems: focus on in vivo microdialysis studies. Jap. J. Pharmac. 70:1996;203-225.
101. 2-adrenoceptor agonist. Molec. Pharmac. 51:1997;36-46.
102. Santiago M., Machado A., Cano J. Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists. Eur. J. Pharmac. 239:1993;83-91.
103. Scatton B. Differential regional development of tolerance to increase in dopamine turnover upon repeated neuroleptic administration. Eur. J. Pharmac. 46:1977;363-369.
104. 3 receptor: from gene to function. The Eighth International Catecholamine Symposium, p. 189.
105. Séguéla P., Watkins K. C., Geffard M., Descarries L. Noradrenaline axon terminals in adult rat neocortex: an immunocytochemical analysis in serial thin sections. Neuroscience. 35:1990;249-264.
106. 1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br. J. Pharmac. 96:1989;283-290.
107. Sharp T., Bramwell S. R., Hjorth S., Grahame-Smith D. G. Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. Br. J. Pharmac. 98:1989;989-997.
108. 1A receptors causes hypothermia in the guinea-pig. J. Psychopharmac. 8:1994;14-21.
109. 1D receptor antagonist GR127935 on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysis. Neuropharmacology. 34:1995;377-382.
110. 1A receptor antagonist. Behav. Brain Res. 73:1996;157-161.
111. 3H-dopamine release in anesthetized, awake and freely moving rats. Brain Res. Bull. 16:1986;161-166.
112. 1A autoreceptors modulate 5-HT release in the guinea pig dorsal raphe nucleus. Neuropharmacology. 33:1994;393-402.
113. 2 dopamine receptors. The Eighth International Catecholamine Symposium, p. 195.
114. 1A receptor activation. Br. J. Pharmac. 115:1995;703-711.
115. 1-adrenoceptor antagonism. J. clin. Psychopharmac. 15:1995;11S-18S.
116. Tanda G., Carboni E., Frau R., Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology. 115:1994;285-288.
117. 3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacology. 119:1995;15-19.
118. 3 receptors inhibit dopamine release. J. Pharmac. exp. Ther. 270:1994;475-479.
119. 2-Adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. Naunyn-Schmiedeberg's Arch. Pharmac. 345:1992;137-143.
120. Taube H. D., Starke K., Borowski E. Presynaptic receptor systems on noradrenergic neurones of rat brain. Naunyn-Schmiedeberg's Arch. Pharmac. 299:1977;123-141.
121. 2-autoreceptors. Naunyn-Schmiedeberg's Arch. Pharmac. 349:1994;25-33.
122. 2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices. Naunyn-Schmiedeberg's Arch. Pharmac. 350:1994;473-481.
123. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotoninergic inhibition. Psychopharmacology. 98:1989;45-50.
124. 3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J. Pharmac. exp. Ther. 271:1994;1558-1565.
125. Vahabzadeh A., Fillenz M. Studies on the origin of rat hippocampal dihydroxyphenylacetic acid using microdialysis. Neurosci. Lett. 136:1992;51-55.
126. Van Veldhuizen M. J. A., Feenstra M. G. P., Boer G. J., Westerink B. H. C. Microdialysis studies on cortical noradrenaline release: basic characteristics, significance of extracellular calcium and massive post-mortem increase. Neurosci. Lett. 119:1990;233-236.
127. Van Veldhuizen M. J. A., Feenstra M. G. P., Heinsbroek R. P. W., Boer G. J. In vivo microdialysis of noradrenaline overflow: effects of α-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves. Br. J. Pharmac. 109:1993;655-660.
128. Van Veldhuizen M. J. A., Feenstra M. G. P., Boer G. J. Regional differences in the in vivo regulation of the extracellular levels of noradrenaline and its metabolites in rat brain. Brain Res. 635:1994;238-248.
129. 2-adrenergic receptor subtypes in brain. Pharmac. Biochem. Behav. 41:1992;267-273.
130. 1A receptors in the rat prefrontal cortex. Eur. J. Pharmac. 305:1996;73-78.
131. 2A receptors in the rat medial prefrontal cortex. Soc. Neurosci. Abstr. 22:1996;68.7.
132. Willner P. (1995) Dopaminergic mechanisms in depression and mania. In Psychopharmacology: The Fourth Generation of Progress (eds Bloom F. E. and Kupfer D. J.), pp. 921-931. Raven, New York.
133. Wolf M. E., Galloway M. P., Roth R. H. Regulation of dopamine synthesis in the medial prefrontal cortex: studies in brain slices. J. Pharmac. exp. Ther. 236:1986;699-707.
134. Zacharko R. M., Anisman H. Stressor-induced anhedonia in the mesocorticolimbic system. Neurosci. Biobehav. Rev. 15:1991;391-405.
135. 2-adrenergic receptor mRNAs in the rat CNS. Molec. Brain Res. 10:1991;219-225.
136. 1A agonist, 8-OH-DPAT, on midbrain DA neurons: A9/A10 differences. Soc. Neurosci. Abstr. 19:1993;563.7.